FDA expedites review of kidney cancer drug

The FDA has added BAY 43-9006, an investigational treatment for metastatic renal cell carcinoma, to its fast track program.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria